Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Remains on Schedule to bring in Bladder Cancer Imaging System to Market
Bladder cancer is the fourth most common cancer in men andexpected to cause more than 17,000 deaths in the United States this year Imagin Medical is advancing its patented bladder cancer visualization technology toward commercialization and FDA approval, expecting the technology to revolutionize blue light cystoscopy procedures and improve patient outcomes in the process Imagin is funding its efforts with $2.165 million raised towards its convertible note offering Rollout of the company’s manufacturing process was delayed about nine months as a result of the COVID-19 pandemic.but Imagin and its production partner remain on its revised schedule The company expects to…